1. Woolf SH, Schoomaker H. Life Expectancy and Mortality Rates in the United States, 1959-2017. JAMA. 2019;322(20):1996-2016.
2. Wilson N, Kariisa M, Seth P, Smith H, Davis NL. Drug and Opioid-Involved Overdose Deaths - United States, 2017-2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):290-7.
3. Scholl L, Seth P, Kariisa M, Wilson N, Baldwin G. Drug and Opioid-Involved Overdose Deaths - United States, 2013-2017. MMWR Morb Mortal Wkly Rep. 2018;67(5152):1419-27.
4. VanHouten JP, Rudd RA, Ballesteros MF, Mack KA. Drug Overdose Deaths Among Women Aged 30-64 Years - United States, 1999-2017. MMWR Morb Mortal Wkly Rep. 2019;68(1):1-5.
5. Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration; 2019.
6. Centers for Disease Control and Prevention. HIV Surveillance Report, 2017. 2018.
7. Vulnerable Counties and Jurisdictions Experiencing or At-Risk of Outbreaks [Internet]. 2016. Available from: https://www.cdc.gov/pwid/vulnerable-counties-data.html.
8. Conrad C, Bradley HM, Broz D, Buddha S, Chapman EL, Galang RR, et al. Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443-4.
9. Lyss SB, Buchacz K, McClung RP, Asher A, Oster AM. Responding to Outbreaks of Human Immunodeficiency Virus Among Persons Who Inject Drugs-United States, 2016-2019: Perspectives on Recent Experience and Lessons Learned. J Infect Dis. 2020;222(Supplement_5):S239-S49.
10. Centers for Disease Control and Prevention. HIV and Women 2019 [updated October 2020. Available from: https://www.cdc.gov/hiv/group/gender/women/index.html.
11. Centers for Disease Control and Prevention. HIV Surveillance Report, 2018. 2020.
12. Batchelder AW, Lounsbury DW, Palma A, Carrico A, Pachankis J, Schoenbaum E, et al. Importance of substance use and violence in psychosocial syndemics among women with and at-risk for HIV. AIDS Care. 2016;28(10):1316-20.
13. Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423-34.
14. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399-410.
15. Zhang C, McMahon J, Simmons J, Brown LL, Nash R, Liu Y. Suboptimal HIV Pre-exposure Prophylaxis Awareness and Willingness to Use Among Women Who Use Drugs in the United States: A Systematic Review and Meta-analysis. AIDS Behav. 2019;23(10):2641-53.
16. Huang YA, Zhu W, Smith DK, Harris N, Hoover KW. HIV Preexposure Prophylaxis, by Race and Ethnicity - United States, 2014-2016. MMWR Morb Mortal Wkly Rep. 2018;67(41):1147-50.
17. Patel AS, Goparaju L, Sales JM, Mehta CC, Blackstock OJ, Seidman D, et al. Brief Report: PrEP Eligibility Among At-Risk Women in the Southern United States: Associated Factors, Awareness, and Acceptability. J Acquir Immune Defic Syndr. 2019;80(5):527-32.
18. Bazzi AR, Biancarelli DL, Childs E, Drainoni ML, Edeza A, Salhaney P, et al. Limited Knowledge and Mixed Interest in Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs. AIDS Patient Care STDS. 2018;32(12):529-37.
19. Sherman SG, Schneider KE, Park JN, Allen ST, Hunt D, Chaulk CP, et al. PrEP awareness, eligibility, and interest among people who inject drugs in Baltimore, Maryland. Drug Alcohol Depend. 2019;195:148-55.
20. Smith DK, Van Handel M, Grey J. Estimates of adults with indications for HIV pre-exposure prophylaxis by jurisdiction, transmission risk group, and race/ethnicity, United States, 2015. Ann Epidemiol. 2018;28(12):850-7.e9.
21. Wu H, Mendoza MC, Huang YA, Hayes T, Smith DK, Hoover KW. Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons-United States, 2010-2014. Clin Infect Dis. 2017;64(2):144-9.
22. Harris N, Johnson, AS., Huang YA., Kern, D., Smith, DK., Valeroy, LA., Hall, I. Vital Signs: Status of Human Immunodeficiency Virus Testing, Viral Suppression, and HIV Preexposure Prophylaxis —United States, 2013–2018. Morbidity and Mortality Weekly Report. 2019;23:1-7.
23. Wechsberg WM, Deren S, Myers B, Kirtadze I, Zule WA, Howard B, et al. Gender-Specific HIV Prevention Interventions for Women Who Use Alcohol and Other Drugs: The Evolution of the Science and Future Directions. J Acquir Immune Defic Syndr. 2015;69 Suppl 2:S128-39.
24. Smith JD, Li DH, Hirschhorn LR, Gallo C, McNulty M, Phillips G, et al. Landscape of HIV Implementation Research Funded by the National Institutes of Health: A Mapping Review of Project Abstracts. AIDS Behav. 2020;24(6):1903-11.
25. Medina-Perucha L, Family H, Scott J, Chapman S, Dack C. Factors Associated with Sexual Risks and Risk of STIs, HIV and Other Blood-Borne Viruses Among Women Using Heroin and Other Drugs: A Systematic Literature Review. AIDS Behav. 2019;23(1):222-51.
26. Adams LM, Kendall S, Smith A, Quigley E, Stuewig JB, Tangney JP. HIV risk behaviors of male and female jail inmates prior to incarceration and one year post-release. AIDS Behav. 2013;17(8):2685-94.
27. Noska AJ, Roberts MB, Sufrin C, Stein LA, Beckwith CG, Rich JD, et al. History of Sex Exchange in Women with a History of Incarceration. J Health Care Poor Underserved. 2016;27(2a):149-62.
28. Loeliger KB, Biggs ML, Young R, Seal DW, Beckwith CG, Kuo I, et al. Gender Differences in HIV Risk Behaviors Among Persons Involved in the U.S. Criminal Justice System and Living with HIV or at Risk for HIV: A "Seek, Test, Treat, and Retain" Harmonization Consortium. AIDS Behav. 2017;21(10):2945-57.
29. Zhu GA, Birnbaum N, Carroll-Scott A, Evans L, Fiellin LE, Wang EA. Gender differences in HIV risk behaviors in individuals recently released from prison: results of a pilot study. Health & Justice. 2015;3(1):6.
30. Stone J, Fraser H, Lim AG, Walker JG, Ward Z, MacGregor L, et al. Incarceration history and risk of HIV and hepatitis C virus acquisition among people who inject drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18(12):1397-409.
31. Hill CE, Knox S, Thompson BJ, Williams EN, Hess SA. Consensual qualitative research: An update. J Couns Psychol. 2005;52(2):196-205.
32. Barbour RS. Checklists for improving rigour in qualitative research: a case of the tail wagging the dog? BMJ. 2001;322(7294):1115-7.
33. Centers for Disease Control and Prevention. HIV in the United States and Dependent Areas. 2019.
34. Collier KL, Colarossi LG, Sanders K. A PrEP Information and Self-Screening Tool for Women. AIDS Educ Prev. 2018;30(1):13-25.
35. Rutledge R, Madden L, Ogbuagu O, Meyer JP. HIV Risk perception and eligibility for pre-exposure prophylaxis in women involved in the criminal justice system. AIDS Care. 2018;30(10):1282-9.
36. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2017.
37. Meyer JP, Muthulingam D, El-Bassel N, Altice FL. Leveraging the U.S. Criminal Justice System to Access Women for HIV Interventions. AIDS Behav. 2017;21(12):3527-48.
38. DiFiore J. New York State’s Opioid Intervention Court. In: National Center for State Courts, editor. 2018.
39. Hershow RB, Gonzalez M, Costenbader E, Zule W, Golin C, Brinkley-Rubinstein L. Medical Providers and Harm Reduction Views on Pre-Exposure Prophylaxis for HIV Prevention Among People Who Inject Drugs. AIDS Educ Prev. 2019;31(4):363-79.
40. Glick JL, Russo R, Jivapong B, Rosman L, Pelaez D, Footer KHA, et al. The PrEP Care Continuum Among Cisgender Women Who Sell Sex and/or Use Drugs Globally: A Systematic Review. AIDS Behav. 2020;24(5):1312-33.
41. Peterson M, Macmadu A, Truong AQ, Rich J, Pognon K, Lurie M, et al. Pre-exposure prophylaxis awareness and interest among participants in a medications for addiction treatment program in a unified jail and prison setting in Rhode Island. J Subst Abuse Treat. 2019;106:73-8.
42. Qin Y, Price C, Rutledge R, Puglisi L, Madden LM, Meyer JP. Women's Decision-Making about PrEP for HIV Prevention in Drug Treatment Contexts. Journal of the International Association of Providers of AIDS Care. 2020;19:2325958219900091.
43. Ridgway J, Almirol E, Schmitt J, Bender A, Anderson G, Leroux I, et al. Exploring Gender Differences in PrEP Interest Among Individuals Testing HIV Negative in an Urban Emergency Department. AIDS Educ Prev. 2018;30(5):382-92.
44. Nakasone SE, Young I, Estcourt CS, Calliste J, Flowers P, Ridgway J, et al. Risk perception, safer sex practices and PrEP enthusiasm: barriers and facilitators to oral HIV pre-exposure prophylaxis in Black African and Black Caribbean women in the UK. Sex Transm Infect. 2020;96(5):349-54.
45. Bradley E, Forsberg K, Betts JE, DeLuca JB, Kamitani E, Porter SE, et al. Factors Affecting Pre-Exposure Prophylaxis Implementation for Women in the United States: A Systematic Review. Journal of women's health (2002). 2019;28(9):1272-85.
46. Hill LM, Lightfoot AF, Riggins L, Golin CE. Awareness of and attitudes toward pre-exposure prophylaxis among African American women living in low-income neighborhoods in a Southeastern city. AIDS Care. 2020:1-5.
47. Footer KHA, Lim S, Rael CT, Greene GJ, Carballa-Diéguez A, Giguere R, et al. Exploring new and existing PrEP modalities among female sex workers and women who inject drugs in a U.S. city. AIDS Care. 2019;31(10):1207-13.
48. Hartmann M, Lanham M, Palanee-Phillips T, Mathebula F, Tolley EE, Peacock D, et al. Generating CHARISMA: Development of an Intervention to Help Women Build Agency and Safety in Their Relationships While Using PrEP for HIV Prevention. AIDS Educ Prev. 2019;31(5):433-51.
49. Hotton AL, French AL, Hosek SG, Kendrick SR, Lemos D, Brothers J, et al. Relationship Dynamics and Sexual Risk Reduction Strategies Among Heterosexual Young Adults: A Qualitative Study of Sexually Transmitted Infection Clinic Attendees at an Urban Chicago Health Center. AIDS Patient Care STDS. 2015;29(12):668-74.
50. McLaurin-Jones TL, Lashley MB, Marshall VJ. Using Qualitative Methods to Understand Perceptions of Risk and Condom Use in African American College Women: Implications for Sexual Health Promotion. Health Educ Behav. 2017;44(5):805-14.
51. Parker L, Pettifor A, Maman S, Sibeko J, MacPhail C. Concerns about partner infidelity are a barrier to adoption of HIV-prevention strategies among young South African couples. Cult Health Sex. 2014;16(7):792-805.
52. Wingood GM, DiClemente RJ. Partner influences and gender-related factors associated with noncondom use among young adult African American women. Am J Community Psychol. 1998;26(1):29-51.
53. Braksmajer A, Senn TE, McMahon J. The Potential of Pre-Exposure Prophylaxis for Women in Violent Relationships. AIDS Patient Care STDS. 2016;30(6):274-81.
54. el-Bassel N, Ivanoff A, Schilling RF, Gilbert L, Borne D, Chen DR. Preventing HIV/AIDS in drug-abusing incarcerated women through skills building and social support enhancement: preliminary outcomes. Soc Work Res. 1995;19(3):131-41.
55. Epperson MW, Platais I, Valera P, Barbieri R, Gilbert L, El-Bassel N. Fear, Trust, and Negotiating Safety: HIV Risks for Black Female Defendants. Affilia. 2009;24(3):257-71.
56. Underhill K, Dumont D, Operario D. HIV prevention for adults with criminal justice involvement: a systematic review of HIV risk-reduction interventions in incarceration and community settings. Am J Public Health. 2014;104(11):e27-53.
57. Allen ST, White RH, O'Rourke A, Ahmad NJ, Hazelett T, Kilkenny ME, et al. Correlates of Transactional Sex Among a Rural Population of People Who Inject Drugs. AIDS Behav. 2020;24(3):775-81.
58. Page K, Tsui J, Maher L, Choopanya K, Vanichseni S, Mock PA, et al. Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions. J Acquir Immune Defic Syndr. 2015;69 Suppl 2(0 1):S169-75.
59. Calabrese SK, Willie TC, Galvao RW, Tekeste M, Dovidio JF, Safon CB, et al. Current US Guidelines for Prescribing HIV Pre-exposure Prophylaxis (PrEP) Disqualify Many Women Who Are at Risk and Motivated to Use PrEP. J Acquir Immune Defic Syndr. 2019;81(4):395-405.
60. Przybyla S, LaValley S, St Vil N. Health Care Provider Perspectives on Pre-exposure Prophylaxis: A Qualitative Study. J Assoc Nurses AIDS Care. 2019.
61. Trump Administration Secures Historic Donation of Billions of Dollars in HIV Prevention Drugs [press release]. 2019.
62. Cranston K, Alpren C, John B, Dawson E, Roosevelt K, Burrage A, et al. Notes from the Field: HIV Diagnoses Among Persons Who Inject Drugs - Northeastern Massachusetts, 2015-2018. MMWR Morb Mortal Wkly Rep. 2019;68(10):253-4.
63. Centers for Disease Control and Prevention. Managing HIV and hepatitis C outbreaks among people who inject drugs—A guide for state and local health departments. 2018.
64. Freudenberg N, Heller D. A Review of Opportunities to Improve the Health of People Involved in the Criminal Justice System in the United States. Annu Rev Public Health. 2016;37(1):313-33.
65. Simeone CA, Seal SM, Savage C. Implementing HIV Testing in Substance Use Treatment Programs: A Systematic Review. J Assoc Nurses AIDS Care. 2017;28(2):199-215.